Tom Peters: McKinsey’s work on opioid sales represents a new low

The author is an writer on administration and his next e book is ‘Excellence Now: Extreme Humanism’

This month McKinsey agreed to shell out approximately $600m to settle claims that its tips had exacerbated the fatal US opioid crisis.

The consultancy suggested Purdue Pharma on having to pay “rebates” to pharmacies based mostly on the amount of folks who died or grew to become addicted soon after having the company’s painkiller OxyContin. 1 2017 presentation bloodlessly calculated that if Purdue paid out $fourteen,810 for every “event”, and two,484 customers of the CVS pharmacy chain overdosed or grew to become addicted in 2019, Purdue would shell out CVS $36.8m that year.

As a McKinsey alumnus, my response was just: “Dear God!” My many years of satisfaction in the agency evaporated as I read through of the settlement. In actuality, I asked a colleague, in earnest: “Should I get rid of McKinsey

Read More